View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. GP Pharm
26 November 2008

GP Pharm Concludes Final Reports for Preclinical Studies Of Sarcodoxome®

Final reports for preclinical studies for GP Pharm’s Liposomal Doxorubicine Sarcodoxome® have been released. Those studies are related to one of the major safety improvements of GP Pharm’s formulation and were performed at department of human toxicology, faculty of health, medicine and life sciences.

One of the University of Maastricht’s studies was a comparison of the cardiotoxicity of Liposomal Doxorubicin GP Pharm with free doxorubicin in the mouse using ECG Telemetry Conclusion. Based on the results of this study, it can be conclude that Liposomal doxorubicin GP Pharm is less cardiotoxic than free doxorubicin.

Another study was that of Lipocroman-6, which investigated the activity of a new antioxidant in a LPO (lipid peroxidation) in vitro system. Based on the results of this study, it can be concluded that Lipocroman-6 reduces lipid peroxidation in vitro.

GP Pharm: Injectable Products for the Urology, Oncology, CNS and CVS Fields
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology